Robert Thomas Webb bought $340k of ARDT
director at Ardent Health Partners, Inc.. 20,000 shares at an average of $16.98, traded Nov 8, 2024, filed Nov 13, 2024.
Score components
- +15RoleDirector
- +15Trade size$340k at market
- +10Relative to holdingsHoldings up 99%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -1.8%, 3m -14.6%, 6m -14.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-24-047644, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 8, 2024 | POpen-market purchase Common Stock | +10,000 | $17.47 | $175k | 30,275 | Nov 13, 2024 |
| Nov 8, 2024 | POpen-market purchase Common Stock | +10,000 | $16.49 | $165k | 40,275 | Nov 13, 2024 |
Related signals
Other insiders at Ardent Health Partners, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 47Moderate | Ardent Health Partners, Inc. | Alfred Lumsdaine Chief Financial Officer | $88k 10,000 shares | +3% | |
| 47Moderate | Ardent Health Partners, Inc. | Robert DeMichiei director | $98k 11,260 shares | +46% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.